TPD52 and colorectal carcinoma: Compared with KLF7 silencing alone, the combined treatment resulted in augmented CRC cell viability (p < .01, Figure 5(c) and enhanced invasion and migration (p < .01, Figure 5(d–e), indicating that TPD52 overexpression partially counteracted the inhibitory effect of KLF7 silencing on CRC cells.